Epidemiologic survey about zoster-associated pain and PHN in herpes zoster patients after antiherpesvirus drug treatment.

Epidemiologic survey about zoster-associated pain and PHN in herpes zoster patients after antiherpesvirus drug treatment. - pain residual rate survey

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000035938

Enrollment

1000

Registered

2019-02-19

Start date

2019-02-26

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

herpes zoster

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1) The patient of herpes zoster, and was prescribed amenamevir Tab. 2) Written informed consent 3) Age >=20 at informed consent

Exclusion criteria

Exclusion criteria: The patient who has the complications that cannot judge a pain due to the herpes zoster exactly.(For example, dementia, lumbago, others)

Design outcomes

Primary

Measure	Time frame
Until disappearance of zoster-associated pain pass, and change time for 12M.	—

Countries

Japan

Contacts

Public ContactYoshitaka Ogaki

EBC&M LLC. Clinical Business Department

yoshitaka_ogaki@ebc-m.com03-6435-3833

Outcome results